Maxime Verhoeven

M.M.A. Verhoeven 1 J. Tekstra 1 P.M.J. Welsing 1 A. Pethö-Schramm 2 M.E.A. Borm 3 G.A.W. Bruyn 4 R. Bos 5 E.N. Griep 6 R. Klaasen 7 J.M. van Laar 1 F.P.J.G. Lafeber 1 J.W.J. Bijlsma 1 M.J.H. de Hair 1 J.W.G. Jacobs 1 1 Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, the Netherlands; 2 F. Hoffmann-La Roche, Basel, Switzerland; 3 Roche Nederland BV, Woerden, the Netherlands; 4 Department of Rheumatology, MC Group, Lelystad, the Netherlands; 5 Department of Rheumatology, Medical Center Leeuwarden, Leeuwarden, the Netherlands; 6 Department of Rheumatology, Antonius Hospital, Sneek, the Netherlands; 7 Department of Rheumatology, Meander Medical Center, Amersfoort, the Netherlands. Published in Rheumatology (Oxford). 2020;59:2325-2333 Chapter 6: Effectiveness and safety over 3 years after the 2-year U-Act-Early trial of the strategies initiating tocilizumab and/or methotrexate.